Romualdo Barroso-Sousa

List of Publications by Year
in descending order

92 papers	4,063 citations	201674 27 h-index	123424 61 g-index
93 all docs	93 docs citations	93 times ranked	6375 citing authors

#	Article	IF	Citations
1	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncology, 2018, 4, 173.	7.1	753
2	Wnt/beta-catenin pathway: modulating anticancer immune response. Journal of Hematology and Oncology, 2017, 10, 101.	17.0	448
3	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 2019, 40, 17-65.	20.1	349
4	Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. PLoS ONE, 2016, 11, e0148142.	2.5	282
5	Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of Oncology, 2020, 31, 387-394.	1.2	244
6	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget, 2015, 6, 34221-34227.	1.8	198
7	Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 2565-2572.	7.0	138
8	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunology Research, 2017, 5, 1133-1140.	3.4	114
9	Quiescent cancer cells resist TÂcell attack by forming an immunosuppressive niche. Cell, 2022, 185, 1694-1708.e19.	28.9	100
10	Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Therapeutic Advances in Medical Oncology, 2016, 8, 261-266.	3.2	93
11	Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care, 2016, 11, 167-173.	1.4	92
12	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptorâ€“Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncology, 2020, 6, 1598.	7.1	84
13	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer, 2018, 124, 1111-1121.	4.1	72
14	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.0	60
15	Optimal treatment of early stage HER2â€positive breast cancer. Cancer, 2018, 124, 4455-4466.	4.1	52
16	Sleep disturbances in patients on maintenance hemodialysis: role of dialysis shift. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2007, 53, 492-496.	0.7	51
17	Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, 2014, 31, 264.	2.5	47
18	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitorâ€“Related Thyroid Disorders. Cancer Immunology Research, 2019, 7, 1214-1220.	3.4	44

#	Article	IF	Citations
19	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 238-245.	2.4	44
20	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica, 2007, 92, 1615-1622.	3.5	39
21	Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncology, The, 2021, 22, e474-e487.	10.7	38
22	Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. Cancer Chemotherapy and Pharmacology, 2007, 61, 215-222.	2.3	34
23	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience, 2016, 10, 609.	1.1	30
24	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Current Oncology Reports, 2018, 20, 1.	4.0	30
25	Evidence to date: talazoparib in the treatment of breast cancer . OncoTargets and Therapy, 2019, Volume 12, 5177-5187.	2.0	30
26	Clinical Development of New Antibodyâ€“Drug Conjugates in Breast Cancer: To Infinity and Beyond. BioDrugs, 2021, 35, 159-174.	4.6	30
27	Complete Resolution of Hypercortisolism with Sorafenib in a Patient with Advanced Medullary Thyroid Carcinoma and Ectopic ACTH (Adrenocorticotropic Hormone) Syndrome. Thyroid, 2014, 24, 1062-1066.	4.5	29
28	Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 793-796.	1.0	27
29	Biological therapies in breast cancer: Common toxicities and management strategies. Breast, 2013, 22, 1009-1018.	2.2	26
30	High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. Oncotarget, 2017, 8, 49470-49483.	1.8	24
31	Genomic Characterization of de novo Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1105-1118.	7.0	24
32	Vatairea macrocarpa (Leguminosae) lectin activates cultured macrophages to release chemotactic mediators. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 374, 275-282.	3.0	22
33	IntoxicaÃ§Ã£o grave por paraquat: achados clÃnicos e radiolÃ³gicos em um sobrevivente. Jornal Brasileiro De Pneumologia, 2010, 36, 513-516.	0.7	22
34	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). Cancer Research, 2022, 82, GS2-10-GS2-10.	0.9	22
35	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	5.2	20
36	Exploring the role of metformin in anticancer treatments: A systematic review. Drugs of Today, 2014, 50, 623.	1.1	20

#	Article	IF	Citations
37	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	12.8	19
38	Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1004-1004.	1.6	19
39	Decreased levels of alpha-1-acid glycoprotein are related to the mortality of septic patients in the emergency department. Clinics, 2013, 68, 1134-1139.	1.5	19
40	The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals of Oncology, 2019, 30, 575-581.	1.2	18
41	Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications. Frontiers in Immunology, 2022, 13, 816642.	4.8	18
42	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Medical Oncology, 2015, 32, 443.	2.5	16
43	PD-1 inhibitors in endometrial cancer. Oncotarget, 2017, 8, 106169-106170.	1.8	15
44	Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Clinics and Practice, 2014, 4, 635.	1.4	13
45	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. Future Oncology, 2019, 15, 2463-2470.	2.4	12
46	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. Current Treatment Options in Oncology, 2020, 21, 59.	3.0	12
47	Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.. Journal of Clinical Oncology, 2018, 36, 1010-1010.	1.6	12
48	Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS1115-TPS1115.	1.6	12
49	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	3.0	11
50	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Medicine, 2021, 13, 89.	8.2	10
51	Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2â˜' locally advanced breast cancer. Brazilian Journal of Medical and Biological Research, 2015, 48, 479-485.	1.5	9
52	Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 192, 86-89.	1.1	9
53	Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. Journal of Clinical Oncology, 2020, 38, 2390-2397.	1.6	9
54	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. Npj Breast Cancer, 2021, 7, 120.	5.2	9

#	Article	IF	Citations
55	Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Global Oncology, 2018, 4, 1-9.	0.5	8
56	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
57	Glutamine depletion potentiates leucocyte-dependent inflammatory events induced by carrageenan or Clostridium difficile toxin A in rats. Immunology, 2005, 116, 328-336.	4.4	7
58	Cardiac Safety of (Neo)Adjuvant Trastuzumab in the Community Setting: A Single-Center Experience. Breast Care, 2014, 9, 255-260.	1.4	6
59	De-escalating treatment in the adjuvant setting in HER2-positive breast cancer. Future Oncology, 2018, 14, 937-945.	2.4	5
60	Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 923-930.	2.4	5
61	Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist, 2021, 26, 927-933.	3.7	5
62	A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1047-1047.	1.6	5
63	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 141-153.	2.4	5
64	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast, 2016, 30, 136-140.	2.2	4
65	Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology, 2019, 3, 1-9.	3.0	4
66	Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 835-841.	1.5	3
67	Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy. Current Breast Cancer Reports, 2019, 11, 272-276.	1.0	3
68	Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC). , 2020, , .		3
69	A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.. Journal of Clinical Oncology, 2018, 36, 1068-1068.	1.6	3
70	Genomic landscape of de novo stage IV breast cancer.. Journal of Clinical Oncology, 2019, 37, 1022-1022.	1.6	3
71	Database Selection and Heterogeneityâ€"More Details, More Credibilityâ€"Reply. JAMA Oncology, 2018, 4, 1295.	7.1	2
72	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. SSRN Electronic Journal, 0, , .	0.4	2

#	Article	IF	Citations
73	Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study. , 2020, , .		2
74	Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i). Cancer Research, 2022, 82, P4-01-06-P4-01-06.	0.9	2
75	Reply to Garcia J. etÂal.. Breast, 2017, 34, 132.	2.2	1
76	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. Stem Cell Investigation, 2019, 6, 4-4.	3.0	1
77	CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer. Translational Cancer Research, 2017, 6, S205-S209.	1.0	1
78	Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research, 2022, 82, OT1-14-02-OT1-14-02.	0.9	1
79	Oral Metronomic Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer Stratified by Prior Docetaxel Therapy. Annals of Oncology, 2012, 23, ix308.	1.2	0
80	Deescalating Treatment in the Adjuvant Setting in Low-Risk HER2-Positive Breast Cancer. , 2019, , 135-142.		0
81	Abstract PD9-08: Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. , 2021, , .		0
82	Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC). , 2021, , .		0
83	Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features.. Journal of Clinical Oncology, 2013, 31, 476-476.	1.6	0
84	Role of paclitaxel and platinum-based chemotherapy in locally advanced and metastatic penile squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15624-e15624.	1.6	0
85	Pretreatment neutrophil to lymphocyte ratio and prognosis of patients with advanced hepatocelullar carcinoma treated with sorafenib.. Journal of Clinical Oncology, 2014, 32, e15144-e15144.	1.6	0
86	Abstract OT1-01-09: Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen. , 2017, , .		0
87	A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, TPS1100-TPS1100.	1.6	0
88	A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1119-TPS1119.	1.6	0
89	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. Journal of the Endocrine Society, 2019, 3, .	0.2	0
90	Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.. Journal of Clinical Oncology, 2019, 37, 517-517.	1.6	0

#	Article	IF	Citations
91	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. Journal of Clinical Oncology, 2020, 38, 2525-2525.	1.6	0
92	Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: A GBECAM multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, e18822-e18822.	1.6	0